ABBOTT-CITALOPRAM TABLET

国家: 加拿大

语言: 英文

来源: Health Canada

有效成分:

CITALOPRAM (CITALOPRAM HYDROBROMIDE)

可用日期:

ABBOTT LABORATORIES, LIMITED

ATC代码:

N06AB04

INN（国际名称）:

CITALOPRAM

剂量:

20MG

药物剂型:

TABLET

组成:

CITALOPRAM (CITALOPRAM HYDROBROMIDE) 20MG

给药途径:

ORAL

每包单位数:

100/500

处方类型:

Prescription

治疗领域:

SELECTIVE-SEROTONIN REUPTAKE INHIBITORS

產品總結:

Active ingredient group (AIG) number: 0136243001; AHFS:

授权状态:

CANCELLED POST MARKET

授权日期:

2015-12-31

产品特点

_ _
_Abbott-Citalopram Product Monograph _
_Page 1 of 48_
PRODUCT MONOGRAPH
PR
ABBOTT-CITALOPRAM _ _
Citalopram Tablets USP
10 mg, 20 mg and 40 mg citalopram (as citalopram hydrobromide)
Antidepressant
BGP Pharma Inc.
8401 Trans-Canada Highway
Saint-Laurent, Quebec
H4S 1Z1
Date of Preparation:
January 7, 2015
Submission Control No.: 180716
_ _
_Abbott-Citalopram Product Monograph _
_Page 2 of 48 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
..................................................................................................12
DRUG INTERACTIONS
..................................................................................................19
DOSAGE AND ADMINISTRATION
..............................................................................25
OVERDOSAGE
................................................................................................................27
ACTION AND CLINICAL PHARMACOLOGY
............................................................28
STORAGE AND STABILITY
..........................................................................................29
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................30
PART II: SCIENTIFIC INFORMATION
...............................................................................31
PHARMACEUTICAL INFORMATION
..........................................................................31
CLINICAL TRIALS
.......................................................................................